Delafloxacin API NEW

Indications:

For the treatment in adults of acute bacterial skin and skin structure infections (ABSSSI) caused by the following sensitive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-sensitive [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus rutin, Streptococcus agalactis, and Streptococcus vascularis (including Streptococcus vascularis, Streptococcus intermedius) And Streptococcus stellatus), Streptococcus pyogenes, Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae and Pseudomonas aeruginosa.

For the treatment of community-acquired bacterial pneumonia (CABP) in adults caused by the following susceptible organisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-sensitive [MSSA] strains only), Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenza, Chlamydia pneumoniae, Legionella pneumoniae and mycoplasma pneumoniae.